Ipsen Announces Analysis Of Managed Medicaid Data Of Children With Cerebral Palsy At Annual Meeting Of The American Academy Of Cerebral Palsy And Developmental Medicine

BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) (Ipsen), today announced a presentation of data from a retrospective study on managed Medicaid costs of treating children with Cerebral Palsy (CP) at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) on September 13-16, 2017 in Montreal, Canada. This data evaluated recent, large-scale, landscape studies of the burden of illness for CP patients in the U.S.

Cerebral Palsy is a term for a group of neurological disorders that appear in infancy or early childhood and affect the part of the brain that controls muscle movements.¹ One of the symptoms associated with CP is spasticity – a condition in which there is an abnormal increase in muscle tone or stiffness in one or more muscles.²

The study objective was to better understand the epidemiology, treatment patterns, resource utilization and associated costs of children with CP in the U.S. Managed Medicaid data from a proprietary database covering 15 states and encompassing seven million lives between 2013-2015 was analyzed, with 3,294 unique cases, which represent patients with CP (aged 2-20) identified through ICD-9/10 diagnosis codes.

The analysis indicates that 42 percent of children diagnosed with CP did not receive any of 10 selected therapies commonly used for spasticity management; these therapies included physical therapy, orthotics, oral baclofen, botulinum toxin, anti-spasm medication, casting, orthopedic surgery, baclofen injection, baclofen pumps, and rhizotomies. These therapies were selected by a group of multidisciplinary researchers and care team members who determined that these methods were the most commonly used spasticity management options for CP patients.

The data also showed the average annual cost of treatment for a child with CP was about 16 times higher than the average cost of treatment for any child enrolled in Medicaid ($22,383 versus $1,359, respectively) between the years 2013 and 2015. Annual costs included expenditure from utilization of pharmacy, medical services, home health, long term care and hospice. Because CP disease severity cannot be obtained from diagnosis codes, the study team developed clinical algorithms to assess the likelihood of ambulation among CP children; 30.5 percent were identified as likely ambulatory, 33.8 percent as likely non-ambulatory, and the remainder unknown. Children with CP that were likely non-ambulatory had average annual costs four times higher than those for children with CP who were likely ambulatory. There was large variability in the medical expenditure for children with CP, even for those with the same ambulatory status. This may be driven in part by regional Medicaid coverage differences. Limitations of this retrospective study include incomplete or inaccurate submitted claims. Further research is needed to understand the specific cost drivers associated with the care of children with CP.

“This study supports the need for a broader look into the overall management plans for children living with Cerebral Palsy, including appropriate treatment options and physical and occupational therapies. We hope this would also lead to better management of costs for families,” said David Cox, VP North American Medical, HEOR & Regulatory Affairs, Ipsen. “Ipsen is committed to improving the care of children with lower limb spasticity – especially those with Cerebral Palsy, the most common motor disability in children.³”

About Ipsen in North America

Ipsen Biopharmaceuticals, Inc. is the US affiliate of Ipsen, a global specialty-driven pharmaceutical group. The US head office is located in Basking Ridge, New Jersey. Ipsen Biopharmaceuticals Canada, Inc. is an integrated business unit within North America and has its head office located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen US research and development center focused on peptide research in oncology and endocrinology, is located in Cambridge, Massachusetts. At Ipsen Bioscience, we focus on creating a highly cooperative and passionate R&D organization through partnerships, innovation, and continuous learning to effectively deliver new treatments for patients. At Ipsen, we focus our resources, investments, and energy on discovering, developing, and commercializing new therapeutic options for oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

Forward Looking Statements

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words “believes,” “anticipates” and “expects” and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfill their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.

© 2017 Ipsen Biopharmaceuticals, Inc.
September 2017 DYS-US-002203